Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neuronetics reports robust Q4 performance, eyes nurse practitioner opportunities

Neuronetics delivered a strong performance in Q4 2022, showcasing revenue growth, operational achievements, and strategic partnerships.
While facing challenges in managing losses and revenue fluctuations, the company is focused on key initiatives and opportunities for future growth.
By leveraging upcoming opportunities with nurse practitioners and addressing analyst inquiries, Neuronetics aims to navigate challenges and drive sustainable growth in 2023.

Neuronetics Inc reports revenue growth and strategic advancements in Q1 2023

Neuronetics Inc's Q1 2023 performance reflects revenue growth, operational advancements, and strategic initiatives aimed at driving market expansion and financial stability.
While facing challenges in gross margin decline and negative EBITDA, the company's focus on cost management, recovery from merger disruption, and revenue guidance raise position it for future success.
With opportunities in expanded patient access, market growth, and product enhancements, Neuronetics is poised to capitalize on its strengths and navigate challenges effectively in the coming quarters.

Neuronetics reports solid Q2 performance, eyes growth amidst challenges

Neuronetics demonstrated resilience and growth in Q2 2023, with revenue increases and strategic advancements in technology and policy.
While facing challenges from closures and relocations, the company remains focused on financial stability and operational efficiency.
Opportunities lie in new technology clearances, favorable policy changes, and the growing demand for TMS therapy education and services.
Overall, Neuronetics' performance, strengths, challenges, and opportunities position the company for continued growth and market impact.

Neuronetics Inc reports solid Q3 earnings, faces challenges in expenses

Neuronetics Inc (STIM) delivered a strong performance in Q3 2023, showcasing revenue growth and operational advancements.
While facing challenges in aligning revenue with operating expenses, the company maintains a solid financial position and pursues growth opportunities.
By focusing on enhancing patient care standards, expanding market reach, and optimizing financial performance, Neuronetics Inc aims to drive sustainable growth and value creation.

Neuronetics Inc posts record revenue in Q4 2023 earnings call

Neuronetics Inc delivered a strong Q4 performance with revenue growth and achieving positive cash flow for the first time. The company's focus on strategic initiatives, regulatory advancements, and revenue guidance for 2024 indicate a positive trajectory for growth and profitability.

Neuronetics Inc reports revenue growth and strategic partnerships in Q1

Neuronetics Inc's Q1 2024 performance reflects revenue growth, operational efficiency improvements, and a strong financial position.
Strengths include successful programs, strategic partnerships, and growth opportunities in new market segments.
Challenges in system sales and revenue collection highlight areas for improvement, while opportunities in market expansion and revenue growth are promising.
Overall, Neuronetics shows resilience, innovation, and a strategic focus on driving growth and improving patient outcomes.

Neuronetics Inc reports Q2 revenue decline, eyes growth opportunities

Neuronetics Inc faced revenue challenges due to a cybersecurity breach but showed resilience in key areas.
Strategic adjustments and positive program results indicate a focus on growth and market expansion.
Acquisition and new debt facility offer opportunities for future expansion and financial stability.

Neuronetics reports solid Q3 earnings, eyes profitability and growth

Neuronetics is focused on optimizing operations, profitability, and cash flow breakeven by Q3 2025.
Greenbrook acquisition approval and strong business position provide a foundation for future growth.
Challenges include managing treatment session weakness and debt levels while pursuing revenue growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

Technological advances reduce time and increase efficiency for MDD treatment Technological advances reduce time and increase efficiency for MDD treatment

NeuroStar TMS Receives Expanded Regulatory Approval in Japan

MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. The Company is scheduled to present at 2:00 pm Eastern Time the same day via webcast.

Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference

New updates designed to advance practice efficiency and patient outcomes New updates designed to advance practice efficiency and patient outcomes

NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements

Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

Neuronetics, Inc. (NASDAQ:STIM ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and CEO Steve Furlong - CFO Conference Call Participants Margaret Kaczor - William Blair Adam Maeder - Piper Sandler Daniel Stauder - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics Third Quarter 2023 Conference Call.

Neuronetics, Inc. (STIM) Q3 2023 Earnings Call Transcript

MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2023.

Neuronetics Reports Third Quarter 2023 Financial and Operating Results

MALVERN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter 2023 financial and operating results prior to market open on Tuesday, November 7th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call

Findings confirm strong correlation between the number of TMS treatment sessions completed and improvement in MDD Findings confirm strong correlation between the number of TMS treatment sessions completed and improvement in MDD

Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes

MALVERN, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced today that it has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners, LLC (“SLR”).

Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility

Portal provides resources to raise awareness around mental health and suicide prevention Portal provides resources to raise awareness around mental health and suicide prevention

In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression

Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. While market conditions appear to have stabilized somewhat, Neuronetics still needs to rein in operating expenses. Neuronetics' current valuation is near all-time lows, which may present an opportunity. Competition and reliance on large investments in sales and marketing present risks though.

Neuronetics: Large Losses May Be Repelling Investors

MALVERN, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is thrilled to announce NeuroStar Advanced Therapy's “Tap Into A New Possibility for Depression” campaign has been awarded Gold by the 2023 dotCOMM Awards in the category of Digital Marketing & Communication Campaigns.

NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards

New automated features elevate the standard of care for NeuroStar® Advanced Therapy practices New automated features elevate the standard of care for NeuroStar® Advanced Therapy practices

Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform

Neuronetics (STIM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Zachary Day - Canaccord Simran Kaur - Piper Sandler Daniel Stauder - JMP Securities Operator Thank you for standing by, welcome to the Neuronetics Second Quarter 2023 Financial and Operating Results Conference Call. At this time al participants' are in a listen-only mode.

Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript

MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2023.

Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results

MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2023 financial and operating results prior to market open on Tuesday, August 8th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call

Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered Lives Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered Lives

Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans

Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment

NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player

The Company expands technology for patients with obsessive-compulsive disorder The Company expands technology for patients with obsessive-compulsive disorder

Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy

Lower Medication Requirement Helps Depression Patients Obtain Treatment Sooner Lower Medication Requirement Helps Depression Patients Obtain Treatment Sooner

Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan

MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023. The Company is scheduled to present at 1:00 pm Eastern Time the same day via webcast.

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy

New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction

The Company is recognized for its commitment to employees' well-being The Company is recognized for its commitment to employees' well-being

Neuronetics Wins 2023 Bell Seal for Workplace Mental Health

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Operator Thank you for standing by, and welcome to the Neuronetics First Quarter 2023 Financial and Operating Results. [Operator Instructions] As a reminder, today's program is being recorded.

News for Neuronetics Inc Stock (STIM)